IM31L
Anti-PAI-1 Mouse mAb (7)
Synonym(s):
Anti-Plasminogen Activator Inhibitor-1
antibody form
purified antibody
clone
7, monoclonal
form
lyophilized
species reactivity
human
isotype
IgG1
General description
Plasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.
Purified mouse monoclonal antibody. Recognizes the latent form of the ~50 kDa PAI-1 protein.
Recognizes the latent form of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
This Anti-PAI-1 Mouse mAb (7) is validated for use in Immunoblotting, Immunoprecipitation for the detection of PAI-1.
Immunogen
partially purified human PAI-1 from conditioned medium of dexamethasone-treated HT1080 cells
Application
Immunoblotting (1 μg/ml)
Immunoprecipitation (see applications refrences)
Immunoprecipitation (see applications refrences)
Physical form
Lyophilized from a volatile buffer, 100 μg BSA.
Preparation Note
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Lyophilized antibodies shou
Analysis Note
Positive Control
Conditioned media from dexamethasone-treated HT-1080 cells
Conditioned media from dexamethasone-treated HT-1080 cells
Other Notes
PAI (Ab-3) will detect latent but not active PAI-1. Antibody should be titrated for optimal results in individual systems.
Legal Information
Sold under license of U.S. Patent 5,422,245.
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Nagayama et al.
Cancer, 73(5), 1398-1405 (1994-03-01)
Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread. In this study, we measured the antigen levels of urokinase (u-PA), tissue plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and type 2 plasminogen
H Pedersen et al.
Cancer research, 54(1), 120-123 (1994-01-01)
The urokinase pathway of plasminogen activation is involved in proteolytic degradation of various tissues, including dissolution of the extracellular matrix and basement membranes during the process of cancer cell invasion. We have studied the prognostic value of urokinase-type plasminogen activator
J Keijer et al.
Blood, 78(2), 401-409 (1991-07-15)
Plasminogen activator inhibitor 1 (PAI-1), an essential regulatory protein of the fibrinolytic system, harbors interaction sites for plasminogen activators (tissue-type [t-PA] and urokinase-type [u-PA]) and for fibrin. In this study, anti-PAI-1 monoclonal antibodies (MoAbs) were used to identify interaction sites
D A Lawrence et al.
The Journal of biological chemistry, 269(21), 15223-15228 (1994-05-27)
Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1
F Blasi et al.
Seminars in cancer biology, 1(2), 117-126 (1990-04-01)
Plasmin formation is an important and complex process in vivo. It involves two enzymes, two inhibitors, the substrate and specific receptors. Plasmin formation, dependent on the urokinase-type plasminogen activator (uPA), is discussed in its biochemical, regulatory and physiological aspects and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service